Ligand Pharmaceuticals Inc (LGND) valuation
Ligand Pharmaceuticals P/E ratio history
Ligand Pharmaceuticals trades at 127.1 times its earnings over the last twelve months and 28.5 times the earnings analysts expect over the next twelve. At its last 5 fiscal year ends its P/E ranged from 3.6 (year to Dec 2019) to 46.7 (year to Dec 2021), with a median of 24.3.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $189.07 | $6.13 | 30.8 | 23.5 |
| Dec 31, 2024 | $107.15 | -$0.22 | n/m | 18.1 |
| Dec 31, 2023 | $71.42 | $2.94 | 24.3 | 16.3 |
| Dec 31, 2022 | $66.80 | -$1.98 | n/m | 20.0 |
| Dec 31, 2021 | $154.46 | $3.31 | 46.7 | 34.4 |
| Dec 31, 2020 | $99.45 | -$0.21 | n/m | — |
| Dec 31, 2019 | $104.29 | $29.34 | 3.6 | — |
| Dec 31, 2018 | $135.70 | $5.60 | 24.2 | — |
| Dec 31, 2017 | $136.93 | — | n/m | — |
| Dec 31, 2016 | $101.61 | — | n/m | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Ligand Pharmaceuticals valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Ligand PharmaceuticalsLGND | $6.47B | 127.1 | 28.5 | 22.3 |
| Hims & Hers HealthHIMS | $6.41B | — | — | 2.5 |
| LantheusLNTH | $6.54B | 24.0 | 17.1 | 4.2 |
| Rhythm PharmaceuticalsRYTM | $6.34B | — | — | 26.4 |
| Kodiak SciencesKOD | $6.21B | — | — | — |
| GrailGRAL | $6.16B | — | — | 37.3 |
| Amneal PharmaceuticalsAMRX | $6.86B | 44.8 | 19.2 | 2.2 |
| ImmunovantIMVT | $5.99B | — | — | — |
| Oruka TherapeuticsORKA | $5.84B | — | — | — |
| Peer median | 34.4 | 18.2 | 4.2 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: LGND financials · LGND returns
No forecast, no recommendation. This page describes Ligand Pharmaceuticals Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.